Title : Endothelial barrier protection by local anesthetics: ropivacaine and lidocaine block tumor necrosis factor-α-induced endothelial cell Src activation.

Pub. Date : 2014 Jun

PMID : 24525631






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine). Ropivacaine tumor necrosis factor Homo sapiens
2 RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine). Ropivacaine tumor necrosis factor Homo sapiens
3 RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine). Ropivacaine tumor necrosis factor Homo sapiens
4 CONCLUSIONS: Ropivacaine and lidocaine effectively blocked inflammatory TNFalpha signaling in endothelial cells by attenuating p85 recruitment to TNF-receptor-1. Ropivacaine tumor necrosis factor Homo sapiens